NO20026166D0 - Substituerte bicykliske derivater for behandling av abnormal cellevekst - Google Patents

Substituerte bicykliske derivater for behandling av abnormal cellevekst

Info

Publication number
NO20026166D0
NO20026166D0 NO20026166A NO20026166A NO20026166D0 NO 20026166 D0 NO20026166 D0 NO 20026166D0 NO 20026166 A NO20026166 A NO 20026166A NO 20026166 A NO20026166 A NO 20026166A NO 20026166 D0 NO20026166 D0 NO 20026166D0
Authority
NO
Norway
Prior art keywords
treatment
cell growth
abnormal cell
substituted bicyclic
bicyclic derivatives
Prior art date
Application number
NO20026166A
Other languages
English (en)
Norwegian (no)
Other versions
NO20026166L (no
Inventor
John Charles Kath
Samit Kumar Bhattacharya
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20026166D0 publication Critical patent/NO20026166D0/no
Publication of NO20026166L publication Critical patent/NO20026166L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20026166A 2000-06-22 2002-12-20 Substituerte bicykliske derivater for behandling av abnormal cellevekst NO20026166L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22
PCT/IB2001/001046 WO2001098277A2 (en) 2000-06-22 2001-06-14 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
NO20026166D0 true NO20026166D0 (no) 2002-12-20
NO20026166L NO20026166L (no) 2002-12-20

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026166A NO20026166L (no) 2000-06-22 2002-12-20 Substituerte bicykliske derivater for behandling av abnormal cellevekst

Country Status (43)

Country Link
US (2) US6890924B2 (ja)
EP (1) EP1292591B1 (ja)
JP (1) JP4044839B2 (ja)
KR (1) KR100545537B1 (ja)
CN (3) CN1437594A (ja)
AP (1) AP2001002192A0 (ja)
AR (1) AR032353A1 (ja)
AT (1) ATE288431T1 (ja)
AU (1) AU2001264159A1 (ja)
BG (1) BG107269A (ja)
BR (1) BR0111548A (ja)
CA (1) CA2413424C (ja)
CZ (1) CZ20023951A3 (ja)
DE (1) DE60108754T2 (ja)
DK (1) DK1292591T3 (ja)
DZ (1) DZ3407A1 (ja)
EA (1) EA005525B1 (ja)
EC (1) ECSP024393A (ja)
EE (1) EE200200710A (ja)
ES (1) ES2236240T3 (ja)
GE (1) GEP20063831B (ja)
HK (1) HK1069576A1 (ja)
HR (1) HRP20021005A2 (ja)
HU (1) HUP0301120A2 (ja)
IL (1) IL152985A0 (ja)
IS (1) IS6616A (ja)
MA (1) MA26914A1 (ja)
MX (1) MXPA02012870A (ja)
MY (1) MY127181A (ja)
NO (1) NO20026166L (ja)
NZ (1) NZ522568A (ja)
OA (1) OA12291A (ja)
PA (1) PA8520301A1 (ja)
PE (1) PE20020257A1 (ja)
PL (1) PL359557A1 (ja)
PT (1) PT1292591E (ja)
SK (1) SK17102002A3 (ja)
SV (1) SV2002000504A (ja)
TN (1) TNSN01091A1 (ja)
UA (1) UA73990C2 (ja)
WO (1) WO2001098277A2 (ja)
YU (1) YU95102A (ja)
ZA (1) ZA200210231B (ja)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
AU2001264159A1 (en) * 2000-06-22 2002-01-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
CA2442742A1 (en) * 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
WO2003045939A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
EP1456199A1 (en) * 2001-12-12 2004-09-15 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2491191C (en) * 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2506503A1 (en) 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
PL377686A1 (pl) * 2002-12-18 2006-02-06 Pfizer Products Inc. Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
KR20050085835A (ko) * 2002-12-19 2005-08-29 화이자 프로덕츠 인코포레이티드 Ｅ-2-메톡시-ｎ-（3-｛4-［3-메틸-4-（6-메틸-피리딘-3-일옥시）-페닐아미노］-퀴나졸린-6-일｝-알릴）-아세트아마이드의 착물, 및 그의 제조방법 및 용도
BRPI0409233A (pt) * 2003-04-09 2006-03-28 Pfizer Prod Inc processos para a preparação de derivados de n-((((piridinilóxi)-fenilaminoquinazolinil)-alil) acetamida e compostos relacionados, bem como intermediários de tais processos e processos para a preparação de tais intermediários
JP2007501854A (ja) * 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
CA2531327A1 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
JP2007533596A (ja) * 2003-07-15 2007-11-22 ナショナル・リサーチ・カウンシル・オブ・カナダ 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2399427T3 (es) 2003-08-14 2013-04-01 Array Biopharma, Inc. Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
RU2328287C2 (ru) * 2003-08-18 2008-07-10 Пфайзер Продактс Инк. Схема приема erbb2 противоопухолевых агентов
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
JP2007510708A (ja) * 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
CN1914182B (zh) 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 喹唑啉衍生物
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
CN101010304A (zh) * 2004-09-01 2007-08-01 三菱制药株式会社 分子伴侣功能调节剂
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PE20080035A1 (es) 2005-09-07 2008-01-30 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PT2090575E (pt) 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
WO2007132307A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
KR20090067169A (ko) 2006-09-11 2009-06-24 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 퀴나졸린 계열 ｅｇｆｒ 억제제
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
PL2387563T5 (pl) 2009-01-16 2023-03-13 Exelixis, Inc. Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (zh) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
CN106232598B (zh) 2014-04-30 2020-03-13 辉瑞公司 环烷基-连接的二杂环衍生物
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
US10287401B2 (en) 2015-07-01 2019-05-14 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
SI3853220T1 (sl) 2018-09-18 2024-04-30 F. Hoffmann-La Roche Ag Derivati kinazolina kot protitumorska sredstva
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (ja) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU756556B2 (en) 1998-10-08 2003-01-16 Astrazeneca Ab Quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
AU2001264159A1 (en) * 2000-06-22 2002-01-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
ES2236240T3 (es) 2005-07-16
JP4044839B2 (ja) 2008-02-06
CA2413424A1 (en) 2001-12-27
PT1292591E (pt) 2005-06-30
YU95102A (sh) 2005-11-28
DE60108754D1 (de) 2005-03-10
JP2004501139A (ja) 2004-01-15
KR100545537B1 (ko) 2006-01-25
UA73990C2 (en) 2005-10-17
EP1292591A2 (en) 2003-03-19
TNSN01091A1 (fr) 2005-11-10
EP1292591B1 (en) 2005-02-02
AP2001002192A0 (en) 2002-12-21
US20020169165A1 (en) 2002-11-14
CN1576275A (zh) 2005-02-09
NZ522568A (en) 2004-12-24
US7332493B2 (en) 2008-02-19
CN1437594A (zh) 2003-08-20
MA26914A1 (fr) 2004-12-20
PA8520301A1 (es) 2003-06-30
DE60108754T2 (de) 2005-06-23
CN1330640C (zh) 2007-08-08
DZ3407A1 (ja) 2001-12-27
PE20020257A1 (es) 2002-04-08
HRP20021005A2 (en) 2004-02-29
EE200200710A (et) 2004-06-15
WO2001098277A3 (en) 2002-06-13
WO2001098277A2 (en) 2001-12-27
BR0111548A (pt) 2003-05-06
HK1069576A1 (en) 2005-05-27
CZ20023951A3 (cs) 2004-01-14
US6890924B2 (en) 2005-05-10
NO20026166L (no) 2002-12-20
US20050159435A1 (en) 2005-07-21
MXPA02012870A (es) 2003-05-14
IL152985A0 (en) 2003-06-24
ECSP024393A (es) 2003-02-06
MY127181A (en) 2006-11-30
HUP0301120A2 (hu) 2003-08-28
ZA200210231B (en) 2004-02-12
KR20030016303A (ko) 2003-02-26
AU2001264159A1 (en) 2002-01-02
SV2002000504A (es) 2002-10-24
OA12291A (en) 2004-03-18
CA2413424C (en) 2007-10-02
IS6616A (is) 2002-11-14
CN101348467A (zh) 2009-01-21
ATE288431T1 (de) 2005-02-15
SK17102002A3 (sk) 2004-04-06
DK1292591T3 (da) 2005-05-30
EA200201277A1 (ru) 2003-06-26
EA005525B1 (ru) 2005-04-28
AR032353A1 (es) 2003-11-05
PL359557A1 (en) 2004-08-23
BG107269A (bg) 2003-06-30
GEP20063831B (en) 2006-05-25

Similar Documents

Publication Publication Date Title
NO20026166L (no) Substituerte bicykliske derivater for behandling av abnormal cellevekst
NO20042882L (no) Kinazolinderivater for behandling av unormal celle vekst
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
NO20053483D0 (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20031442L (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20040278L (no) Fremgangsmate for fremstilling av perindopril
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
IL160971A0 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20000965L (no) FremgangsmÕte for fremstilling av veksthormon-utskillende forbindelser
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
NO20012540D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO20014026D0 (no) Krampestillende derivater til behandling av betydelig skjelving
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20042542L (no) Anvendelse av ascomycin for behandling av blefarit
NO996166L (no) FremgangsmÕte for behandling av avluter